Retargeting antibodies

Details Retargeting antibodies Retargeting antibodies

C - Chemistry, Metallurgy

07

K

C07K 16/46 (2006.01) A61K 39/395 (2006.01) C07K 16/00 (2006.01) C12N 15/11 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2169620

Antibodies are retargeted to a target for which they have no functional specificity under normal circumstances. Use is made of a multi-specific binding substance which has binding specificity for the target and anti-antibody binding specificity. The binding substance may comprise an immunoglobulin antigen binding site and may be a "diabody". Depending on the antibody bound, effector functions such as Complement, ADCC and immune blocking are recruited to act on the target. Example targets are human cells. In vivo and in vitro utilities are exemplified, including lysis of tumor cells and agglutination of red blood cells.

On recible des anticorps pour les diriger sur une cible pour laquelle ils n'ont aucune spécificité fonctionnelle dans des conditions normales. On utilise une substance de liaison multispécifique dotée d'une spécificité de liaison à l'égard de la cible et à l'égard d'un anti-anticorps. La substance de liaison peut comprendre un site de fixation immunoglobuline antigène et peut être un "dianticorps" (anticorps à double spécificité). En fonction de l'anticorps lié, on utilise des fonctions effectrices telles que le Complément, la cytotoxicité cellulaire dirigée par de anticorps (ADCC), et le blocage immun pour agir sur la cible. On peut citer à titre d'exemples de cibles des cellules humaines. Des applications in vivo et in vitro servent d'illustration, y compris la lyse des cellules tumorales et l'agglutination des globules rouges.

Affiliated with

Also associated with

Rating

Retargeting antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Retargeting antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retargeting antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1528438